Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH

Cancer-specific mutations can lead to peptides of unique sequence presented on MHC class I to CD8 T cells. These neoantigens can be potent tumour-rejection antigens, appear to be the driving force behind responsiveness to anti-CTLA-4 and anti-PD1/L1-based therapies and have been used to develop pers...

Descripción completa

Detalles Bibliográficos
Autores principales: Crowley, Stephanie J., Bruck, Patrick T., Bhuiyan, Md Aladdin, Mitchell-Gears, Amelia, Walsh, Michael J., Zhangxu, Kevin, Ali, Lestat R., Jeong, Hee-Jin, Ingram, Jessica R., Knipe, David M., Ploegh, Hidde L., Dougan, Michael, Dougan, Stephanie K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058936/
https://www.ncbi.nlm.nih.gov/pubmed/32019478
http://dx.doi.org/10.1098/rsob.190235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058936/
https://www.ncbi.nlm.nih.gov/pubmed/32019478
http://dx.doi.org/10.1098/rsob.190235

Ejemplares similares